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Stem  cells  are  defined  as  immature  cells 
able  to  proliferate,  self-renew  and  differentiate 
into several more committed cellular types and 
tissues.1 These cells could be generally classified 
in  embryonic  stem  cells  (ESCs)  which  are 
considered pluripotent thanks to their capability to 
give rise to all kinds of cells and adult stem cells. 
These  last  ones  are  just  multipotent  because 
their  differentiation  potential  is  restricted  to 
certain cell lineages. ESCs are derived from the 
early mammalian embryo at the blastocyst stage 
(Figure 1) and under specific culture conditions 
they  can  undergo  unlimited  expansion  in  vitro 
and differentiation.2 On the contrary, adult stem 
cells  are  available  from  many  tissues  such  as 
brain, bone, adipose tissue, umbilical cord blood, 
deciduous  teeth,  synovium,  blood  vessels  and 
blood.3-5 Adult mesenchymal stem cells (MSCs) are 
at the moment highly considered as a cell-based 
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therapeutic  tool  for  a  diverse  range  of  clinical 
purposes. MSCs, in addition to their multipotency, 
are easy to isolate and culture in vitro and they do 
not apparently represent an ethical issue based on 
their source of origin (Table 1).
MSCS: bIoLoGICAL bACKGRouNd
Mesenchymal  stromal  cells  (MSCs)  are 
multipotent  adult  stem  cells,  nonhematopoietic, 
with  mesodermal  and  neuroectodermal  origin. 
They can be found in several and perhaps most 
postnatal organs and tissues like adipose tissue, 
dental pulp, umbilical cord and especially in the 
bone marrow (BM) which appears to be the most 
often  used  source  (Figure  2).  MSCs  are  able  to 
differentiate into cells of mesodermal origin like 
adypocites, chondrocytes or osteocytes, but they 
can  also  give  rise  to  representative  lineages  of 
the  three  embryonic  layers.6  For  instance,  it  is 
well known that MSCs posses an extended degree 
of  plasticity  compared  to  other  adult  stem  cell 
populations, including the ability to differentiate 
in vitro into non-mesodermal cell types such as 
neurons and astrocytes.7 
MSCs can easily be isolated based on plastic 
adherence properties but the lack of one unique 
specific  marker  still  represents  a  challenge  for 
researchers.  That  is  the  reason  why  a  general 
rank of positive and negative surface markers has 
been used to ensure homogeneity of the isolation; 
meaning the presence of CD73, CD90, CD105 and 
lack  of  characteristic  hematopoietic  markers 
such  as  CD14,  CD19,  CD34,  CD45  and  HLA-DR, 
in addition to representative endothelial markers 
like CD318-10 (Table 2).
IMMuNoModuLAtoRY CAPACItY oF 
MSCS
Stem  cell-based  therapy  is  generally  linked 
to  immunorejection  problems  when  the  used 
stem cell-derived tissue is not close or does not 
match  the  patient´s  one.  Several  approaches 
were tried to solve this major issue. Perhaps, the 
most  challenging  one  was  to  reprogram  adult 
somatic  cells  into  the  pluripotent  stage  (iPSCs 
or  induced  pluripotent  stem  cells).  Takahashi 
and Yamanaka11 showed that mouse embryonic 
and adult fibroblasts are able to acquire similar 
properties to ESCs after retroviral introduction of 
genes encoding four transcription factors: Oct3/4, 
Sox2,  Klf4  and  c-Myc.11-13  In  fact,  the  tendency 
was to reduce the number of required genes to 
the minimum. Recently, Zhou et al14 were able to 
generate protein-induced pluripotent stem cells 
(piPSCs) from murine embryonic fibroblasts just 
by using recombinant proteins and consequently, 
Figure  1.  Embryonic  stem  cells  (ESCs)  are  pluripotent  cells 
derived from the early mammalian embryo at the blastocyst 
stage  which  can  undergo  unlimited  expansion  in  vitro  and 
differentiation  into  any  kind  of  cell  lineage,  under  specific 
culture conditions.
Figure  2.  Mesenchymal  stem  cells  (MSCs)  can  be  isolated 
from  distinct  adult  tissue  sources.  These  cells  have  shown 
a  great  plasticity,  being  able  to  undergo  differentiation  into 
representative cell lineages of the three embryonic layers.
CELLS Origin Plasticity Expansion Tumorigenic Ethical obstacles
ESCs Embryo Pluripotent Unlimited Yes Yes
MSCs Adult tissues Multipotent Determined No No
Table 1. ESCs vs. MSCs.
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avoiding  any  risk  of  changing  the  target  cell 
genome by exogenous genetic modification. 
MSCs represent an alternative route to avoid 
immunorejection since they are immunoprivileged 
and  posses  immunomodulatory  properties.15,16 
MSCs are considered immunoprivileged because 
they  are  able  to  be  transplanted  across  major 
histocompatibility  complex  (MHC)  barriers 
making  immunosupression  of  patient  recipients 
unnecessary. These cells escape detection from 
immune  system  thanks  to  their  low  expression 
of  MHC  class  I  and  the  complete  lack  of  MHC 
class II expression.17-19 Their immunomodulatory 
properties  are  not  yet  fully  characterized 
even  though  it  seems  to  implicate  inhibition  of 
proliferation of T cells and consecutive suppression 
of T cells antigen-primed cytolytic effects.20,21
SouRCES FoR MSCS: VERY SIMILAR 
oR REALLY dIFFERENt?
In  principle,  MSCs  can  be  isolated  from 
different sources: Amnion, placenta, bone marrow 
(BM),  umbilical  cord  and  cord  blood,  adipose 
tissue and dental pulp are the most common ones 
(Figure 2). Moreover, these cells are available in 
virtually all post-natal tissues. There, they occupy 
a  perivascular  niche  to  support  and  maintain 
different  connective  and  skeletal  tissues.22  This 
fact makes very probable that other new sources 
may come up in the future since MSCs obtained 
from  different  places  show  close  phenotypic 
characteristics.  However,  it  is  still  unclear 
whether we may be dealing with the same MSCs 
or  not  because  proliferation  and  differentiation 
capabilities  in  the  presence  of  different  growth 
factor  stimulus  do  differ  depending  on  the 
source  of  origin.  For  instance,  bone  marrow 
mesenchymal  stem  cells  (BM-MSCs)  have  a 
tendency to loose their proliferative potential with 
age and it is notorious the lost of differentiation 
capabilities after age 20.23 On the contrary, it has 
been shown that mesenchymal stem cells from 
the dental pulp (DPSCs) have higher proliferation 
index  and  growth  potential  even  though  both 
stem cell populations (BM-MSCs and DPSCs) still 
express very close surface markers such as Stro-
1, CD44, 3G5, CD146 and CD106.23 As a matter of 
fact, Wagner et al24 performed a gene expression 
profile study of MSCs coming from different origins 
(bone marrow, adipose tissue and cord blood) and 
compared them to HS68 fibroblasts. They showed 
that, though MSCs coming from different donors 
and exposed to the same culture conditions gave 
rise to a stable and reproducible gene expression 
profile, MSCs from different sources or cultured 
with different procedures differentially expressed 
many genes. On the contrary, no differences were 
found in a subset of 22 surface antigen markers 
suggesting that MSCs from different origin may 
share common phenotypic and receptor expression 
but indeed, they seem to be distinct at the genetic 
level. Peculiar differences are also seen in their 
differentiation  potential  where  certain  MSCs 
have been reported to show either tendencies or 
difficulties  to  differentiate  into  specific  cellular 
lineages.  For  instance,  DPSCs  predominantly 
differentiate  into  bone  and  neurons25,26  and  it 
has  already  been  described  unsuccessful  trials 
for  adipogenic  differentiation  in  umbilical  cord 
mesenchymal  stem  cells  (UC-MSCs).27  Taking 
all  these  facts  together  we  may  conclude  that 
even  general  biological  characteristics  of  MSCs 
coming from different sources are common and 
comparable, major differences come up in terms 
of  expansion  and  differentiation  potential  which 
should be taken under consideration before future 
clinical and therapeutic approaches.
tHE dENtAL PuLP StEM CELL NICHE
After injury, the dental pulp (Figure 3) plays a 
major role in tooth regeneration by participating in 
a process called reparative dentinogenesis, where 
cells  create  and  accumulate  new  dentin  matrix 
to  repair  the  damaged  area.28  Bigger  traumas 
or advanced caries, for instance, can eventually 
cause the death of the pre-existing population of 
odontoblast.29 As consequence, new odontoblasts 
are  recruited  in  order  to  differentiate  at  the 
injured area and to form reparative dentine, also 
Positive (+) Negative (-)
CD73 CD14
CD90 CD19
CD105 CD31
CD34
CD45
HLA-DR
Table 2. General surface markers for MSCs.
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known  as  osteodentine.  This  early  mineralized 
tissue  preserves  the  pulp  integrity  and  serves 
as protective barrier upon the injury.30 Then, one 
can speculate that dentinogenic progenitors may 
be  located  in  that  area  of  the  dental  pulp  and 
in  fact,  some  studies  have  already  showed  the 
existence  of  a  population  of  putative  post-natal 
stem  cells  or  dental  pulp  stem  cells  (DPSCs) 
which  may  play  a  relevant  role  in  reparative 
dentine formation.31 DPSCs can be considered as 
a  heterogeneous  population  of  MSCs  since  the 
dental pulp is composed from both mesenchymal 
and ectodermic components. Probably, they may 
be located in the perivascular area of the pulp as 
expression of characteristic markers suggest. For 
instance, VCAM-1 and α-smooth-muscle actin are 
positively expressed in these cells.32 Despite of the 
multipotential capabilities of these cells and even 
though their primary commitment seem to be the 
production  of  mineralized  tissue,33  DPSCs  have 
been  shown  to  be  able  to  generate  functionally 
active neurons under determined environmental 
conditions.25  This  neuronal  differentiation 
potential together with their accessibility makes 
DPSCs  a  good  candidate  of  study  for  future 
cell-based  therapy  in  spinal  cord  injury  and 
neurodegenerative diseases.
tHERAPEutIC APPLICAtIoNS oF 
MSCS: tHE tooL boX 
MSCs exhibit a great potential for cell-based 
therapy  in  several  diseases  of  different  nature. 
Basically, these cells have a set of characteristics 
that  somehow  makes  them  adequate  for 
clinical  trials.  They  have  an  optimal  expansion 
potential  and  genetic  stability,  there  are  really 
well  established  protocols  of  isolation  and  new 
sources keep on coming up apart from the already 
existing ones. Moreover, MSCs are able to migrate 
to  areas  of  tissue  damage  in  immunoprivileged 
conditions  and  posses  immunosuppressive 
properties.  All  these  advantages  have  allowed 
successful MSC transplantations (both autologous 
and  heterologous).34-36  The  current  scenario  of 
directly  transplanting  MSCs  in  vivo  to  different 
disease animal models and straight to the injured 
sites is changing nowadays. Recent progresses in 
nanotechnology and a better understanding of the 
molecular pathways that control the differentiation 
program  made  possible  the  combination  of 
biocompatible scaffolds with MSCs, for instance. 
Genetic regulation of the cells within the scaffold, 
in order to achieve secretion of specific proteins 
that may benefit cell integration and tissue repair, 
would  be  doable  with  this  new  combination  of 
strategies.37-39 
Treatment of neurological disorders
A  number  of  studies  have  already  shown 
that  MSCs  are  able  to  differentiate  into  non- 
mesenchymal lineages as a result of their great 
plasticity.  These  multipotent  cells  are  able  to 
give rise to both neurons and astrocytes in vitro 
and  in  vivo.40,41  Probably,  the  most  important 
aspect for the use of these cells in neurological 
cell-based treatments was achieved when direct 
transplantation  of  MSCs  into  a  rodent  brain 
stroke  model  resulted  to  be  safe  and  indeed 
improved  functional  deficits  associated  with  the 
insult.42 One can speculate then, that MSCs may 
be the most feasible option to treat brain stroke 
insults  and  its  devastating  consequences  in 
humans. Several trials were performed in other 
neurological disease models. Mazzini et al,43 for 
instance, started experiments with MSCs in the 
context of amyotrophic lateral sclerosis (ALS); a 
severe disease that leads to specific loss of motor 
neurons. As a result, a chronic decline in muscle 
functionality ends up in gradual paralysis of the 
patient. Mazzini et al43 implanted autologous BM-
MSCs  in  the  spinal  cord  of  monitored  patients 
with  ALS  demonstrating  tolerance  and  most 
importantly, safety of the procedure. 
In general, different neurodegenerative states 
were  taken  on  consideration  for  therapeutic 
Figure  3.  The  human  dental  pulp  contains  a  population  of 
putative post-natal stem cells or dental pulp stem cells (DPSCs) 
with multipotential capabilities. After severe injury, the dental 
pulp stem cell niche may play a critical role in reparative dentine 
formation of the tooth. 
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approaches  of  neuronal  circuitry;  Parkinson´s 
disease, Hungtinton´s disease, multiple sclerosis 
and Alzheimer´s disease are some examples. 
Spinal cord fusion
A  variety  of  cell  transplantation  approaches 
have  been  tested  in  different  spinal  cord  injury 
models.  Spinal  cord  injury  treatment  is  one  of 
the areas with bigger expectations for stem cell-
based therapy. Lesions at the spinal cord triggers 
a number of biochemical cascades that are linked 
to  progressive  reduction  in  blood  supply  to  the 
injured  site.  This  event  actually  multiplies  the 
extent of damaged tissue. In parallel, proliferation 
of fibroblasts together with endothelial and glial 
cells (astrocytes and microglia) at the injured area 
eventually constituting a biological scar that will 
act as both physical and chemical wall.44 Moreover, 
axonal  growth  and  its  guidance  are  prevented 
since both Schwann cells and neurotrophic factor 
are lacking and production of post-injury myelin-
associated proteins is enhanced. Those molecules 
(for instance, Nogo-A) act as inhibitors of neurite 
outgrowth in the central nervous system.45 As a 
final  result,  all  these  events  lead  to  a  deficient 
regenerative  capacity  after  trauma  and  the 
biggest obstacle for the development of definitive 
spinal cord injury treatments. The use of MSCs 
for the treatment of spinal cord injury seems to 
be an exciting option. In fact, it has already been 
described that transplanted MSCs led to a large 
numbers  of  surviving  cells  and  formed  guiding 
strands  in  the  injured  spinal  cord.46  To  repair 
neural  networks,  these  cells  should  in  addition 
demonstrate  integration  into  the  injured  host 
tissue,  potential  to  make  synapses  with  host 
neurons  as  well  as  capabilities  to  achieve  the 
specific required neural phenotype that is missing 
because  of  the  disease  process.  We  have  to 
remember that MSC differentiation into undesired 
tissues  has  been  reported  as  well.  This  makes 
crucially  necessary  the  acquisition  of  strong 
biological  knowledge  about  the  behaviour  and 
differentiation program of these cells, before any 
clinical trial could be performed in humans.47
Kidney repair
Different  adult  stem  cells  have  been  shown 
to differentiate into mature kidney cells, opening 
the question whether post-natal stem cells may 
be a potential tool for renal repair after systemic 
administration. Some studies in different models of 
kidney injury have suggested a role of resident bone 
marrow stem cells in kidney repair.48,49 Poulsom 
et al50 showed in mice that, after receiving bone 
marrow  transplantation,  circulating  stem  cells 
could be recruited to the site of injury overcoming 
acute kidney failure. Since the bone marrow (BM) 
contains  at  least  a  couple  of  known  stem  cell 
populations,  haematopoietic  stem  cells  (HSCs) 
and MSCs, these last ones may be responsible for 
improvement  in  a  renal  damage  scenario,  even 
though it remains unclear the actual number of 
MSCs in the adult kidney and whether they would 
be  the  only  sufficient  population  of  stem  cells 
involved in the recovery. Despite the discrepancies 
about the mechanism, MSCs have been reported 
to  protect  against  chemical-induced  toxicity 
(cisplatin  and  glycerol)  in  mice,  and  in  case  of 
glycerol,  MSC  mobilization  into  the  damaged 
kidney seemed to be dependent on the presence 
of CD44. Kidneys damaged by injection of glycerol 
overexpressed  hyaluronic  acid  (HA)  and  MSCs 
isolated from mice lacking CD44, the receptor for 
HA, were unable to migrate to injured sites of the 
kidneys.51,52 On the contrary, other chronic disease 
models  showed  no  association  between  MSCs 
and improvement in renal function and/or animal 
survival.53  Nevertheless,  additional  knowledge 
about  MSC  transmigration  mechanisms  and 
differentiation into renal cells is required in order 
to consider MSCs as a future cellular source for 
kidney repair.
Joint regeneration in rheumatic diseases
Joint degeneration usually comes as a parallel 
event  to  degenerative  arthritis  (osteoarthritis, 
OA)  or  rheumatoid  arthritis  (RA).  Like  other 
autoimmune  diseases,  they  develop  as  a  result 
of immunologic instability and loss of tolerance. 
Then, the immune system starts to react against 
self  structures  and  tissues  of  the  organism 
leading  to  gradual  reduction  of  extracellular 
matrices  in  joint  cartilage  and  bone.  In  these 
cases, therapy is focused in alleviating symptoms 
and/or  changing  the  disease  progress  but 
never  restores  joint  structure  and  functionality. 
Moreover,  resistance  for  conventional  therapy 
of  anti-inflammatory  and  immunosuppressive 
drugs has been reported in some patients, making 
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necessary the use of extremely high doses which 
are normally associated to side effects. Therefore, 
in  these  particular  cases,  BM  restoration  is 
recommended.54 It has already been shown that 
chondrogenic activity of MSCs is clearly reduced 
in patients with advanced osteoarthritisis.55 
In  fact,  MSCs  has  been  proposed  as  cell 
candidates  for  tissue  engineering  approaches 
in  joint  cartilage  and  bone  defects  repair, 
mainly  because  of  their  ability  to  substitute 
chondrocytes and immunomodulatory properties. 
Immunoprivileged  status  of  MSCs  became  this 
particular type of stem cell an option to consider 
for allogeneic transplants with the advantages of 
an autologous one but it is still on debate whether 
the plasticity and differentiation potential remains 
the  same  in  both  cases.56,57 Their  capabilities  of 
creating new joint tissues and secreting different 
bioactive factors provide the adequate regenerative 
environment.58 Among all possible molecules and 
pathways  modulating  osteogenic  differentiation, 
SOX9  seems  to  be  critical.  Tsuchiya  et  al59 
showed that in BM derived-MSCs, the expression 
of exogenous SOX9 led to increased proteoglycan 
deposition. It has also been described that WNT 
signalling  controls  MSC  fate  decisions  and  this 
role is probably played in cooperation with other 
signalling pathways such as TGF-β and BMPs.60-
62  Nowadays,  treatment  of  cartilage  trauma 
coexists  with  almost  null  regenerative  potential 
and  for  that  purpose  MSCs  seem  to  be  a  good 
option for human tissue engineered cartilage, in 
combination  with  new  nanotechnological  tools, 
biomaterials and different growth factors that may 
help  propagation,  integration  and  differentiation 
of such cells.63
Therapy for cardiac disease
Cardiovascular failure is the leading cause of 
death worldwide.64 Most of the current therapies 
just delay progression mainly because of heart’s 
weak  capacity  to  self-regenerate.65  Since  heart 
failure  is  directly  linked  to  cardiomyocyte 
death  and  loss  of  myocardial  cell  mass,  stem 
cell  therapy  has  strongly  come  up  as  a  novel 
therapeutic  option  to  treat  cardiac  disease.66,67 
Different  cells  such  as  hematopoietic  stem 
cells, endothelial progenitor cells, cardiac stem 
cells, ES cells and MSCs were on debate as the 
most adequate one for that approach; especially, 
adult  bone  marrow  derived  stem  cells  which 
were  reported  to  improve  myocardial  function 
after infarction.68,69 In fact, results from different 
laboratories  demonstrated  that  MSCs,  under 
specific  conditions  (exposition  to  grow  factors 
and/or  diverse  chemical  compounds),  are  able 
to give rise to cardiomyocyte-like cells.70-72 These 
differentiation potential has also been described in 
vivo but at lower rates and one can never exclude 
the  possibility  of  getting  additional  unwished 
differentiated cell types. For instance, Breitbach 
et al described the development of encapsulated 
areas  with  calcifications  and/or  ossification  at 
myocardial  sites  after  MSC  transplantation  in  a 
cryo-infarction animal model.47,73 Indeed, several 
questions remain with no answer at many levels 
and  whether  MSCs  may  be  the  best  model  for 
cardiovascular repair is still to be shown.
Skin regeneration
Wound  healing  is  a  complicated  biological 
process where several kinds of cells are required, 
extracellular matrix (ECM) deposition is needed and 
different regulatory events such as angiogenesis 
should be well coordinated.74,75 This process gets 
relevant  when  it  comes  to  patients  suffering 
diabetes.76,77  Foot  ulcers  are  relatively  common 
among patients with diabetes and they easily get 
infected. If the infection is not properly treated and 
finally extends, it could lead to foot amputation for 
septic gangrene. Wound healing is an extremely 
important  event  in  burned  patients  too.  In  this 
scenario,  infections  are  also  the  most  general 
complication especially in highest degree burns. 
Two stem cell niches are probably involved in the 
repair of the damaged tissue: stem cells from the 
injured tissue itself and/or migratory stem cells 
from bone marrow (MSCs and hematopoitic stem 
cells). Thus, MSCs may migrate from bone marrow 
to damaged tissues in order to reconstitute skin in 
cutaneous wounds.78 Burn wound animal models 
have already been tried demonstrating that tissue-
engineered skin containing MSCs can accelerate 
wound healing successfully. Wounds grafted with 
MSCS  showed  better  epidermal  formation  and 
increased  vascularisation.79  In  fact,  Wu  et  al80 
showed that BM-MSCs are able to promote wound 
repair  through  differentiation  and  production  of 
proangiogenic  factors  like  vascular  endothelial 
growth  factor  (VEGF)  and  angiopoietin-1.  Better 
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understanding  about  this  mechanism  may 
contribute to develop novel therapies for severe 
cutaneous status like the ones mentioned above 
as well engineering new skin substitutes. 
Tooth engineering
Tooth  loss  is  often  associated  with  both 
physiological  and  pathological  causes  that 
include aging, trauma, dental caries, periodontal 
diseases as well as genetic reasons. In addition 
to  physical  limitations,  tooth  loss  affects 
facial  esthetic  and  decreases  quality  of  life.81 
Nowadays,  different  research  groups  are 
working  in  the  development  of  new  stem-cell-
based  tissue  engineering  approaches  for  tooth 
regeneration.82-84  Recent  strategies  focus  on 
combination  of  several  scaffolding  biomaterials, 
where cells are seeded, together with controlled 
release  of  signalling  cues  for  stem  cells.37,85,86 
These kinds of polymer scaffolds, like polyglycolic 
acid (PGA) or poly (lactic-co-glycolic) acid (PLGA), 
are  biodegradable  and  permit  implantation  of 
cell-scaffold constructs on the host, revealing a 
promising option for tooth regeneration. Besides, 
MSCs  from  dental  pulp  and  bone  marrow  have 
been proposed as potential candidates for tooth 
engineering.  Indeed,  it  was  reported  that  both 
populations are able to successfully form different 
dental  structures  under  specific  conditions.87-91 
Moreover, Yu et al92 concluded that DPSCs showed 
the highest odontogenic capability under the same 
inductive  microenvironment  in  comparison  to 
bone marrow stromal stem cells. But despite of 
its potential, a number of obstacles such as shape, 
size  and  growth  control  of  the  new  developing 
bio-engineered  tooth  and  availability  of  dental 
epithelium as well as graft rejection in the jaws 
are still challenging researchers in the field.93
CoNCLuSIoNS
Interest about novel stem cell-based therapies 
has exponentially been increasing over the past 
years,  not  only  in  the  scientific  community  but 
also within the society. Indeed, stem cells seem to 
give the best chance for human tissue engineering 
and particularly, hMSCs, may be a great tool in 
regenerative medicine because of their ability to 
differentiate into a variety of specialized cells in 
addition to their immunoprivileged characteristics. 
However,  caution  is  always  recommended  to 
ensure safety and success of clinical trials. More 
detailed data concerning biological and functional 
properties of MSCs is still required. In this review, 
we wanted to summarize the general landscape 
of the MSC tool box for bioengineering, which may 
provide in the future new therapeutic strategies 
for a range of diseases with no cure so far.  
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